Inhibace

LEAFLET INCLUDED IN THE PACKAGING: INFORMATION FOR THE PATIENT

Warning! Keep the leaflet! Information on the immediate packaging in a foreign language.

Inhibace

5 mg, coated tablets

cylazapril

You should carefully read the contents of the leaflet before using the medicine, as it contains important information for the patient.

• You should keep this leaflet, so that you can read it again if you need to.
• In case of any doubts, you should consult a doctor or pharmacist.
• This medicine has been prescribed specifically for you and you should not pass it on to others, as it may harm them, even if their symptoms are the same as yours.
• If the patient experiences any side effects, including those not listed in this leaflet, they should tell their doctor or pharmacist. See section 4.

Table of contents of the leaflet:

• 1. What is Inhibace and what is it used for
• 2. Important information before taking Inhibace
• 3. How to take Inhibace
• 4. Possible side effects
• 5. How to store Inhibace
• 6. Contents of the packaging and other information

1. What is Inhibace and what is it used for

Inhibace contains the active substance cylazapril.
Inhibace is used to treat:

• high blood pressure (hypertension);
• chronic (long-term) heart failure.

Cylazapril belongs to a group of medicines called ACE inhibitors (angiotensin-converting enzyme inhibitors). The action of this medicine is to relax and dilate blood vessels. This helps to lower blood pressure. It also makes it easier for the heart to pump blood in patients with chronic heart failure.
The doctor may prescribe other medicines to be taken at the same time as Inhibace.

2. Important information before taking Inhibace

When not to take Inhibace:

• if the patient is allergic (hypersensitive) to cylazapril or any of the other ingredients of this medicine (listed in section 6);
• if the patient is allergic (hypersensitive) to other ACE inhibitors. These include captopril, enalapril, lisinopril, and ramipril;
• if the patient has experienced a severe side effect called angioedema after taking other ACE inhibitors. If the patient has hereditary angioedema or angioedema of unknown cause. Symptoms include swelling of the face, lips, mouth, or tongue. Patients taking certain oral anti-diabetic medicines or medicines that suppress the immune system are at increased risk of angioedema;
• after the third month of pregnancy (it is also recommended to avoid taking Inhibace in early pregnancy - see "Pregnancy" and "Breast-feeding");
• if the patient has diabetes or kidney problems and is being treated with a blood pressure-lowering medicine containing aliskiren;
• if the patient has taken or is currently taking sacubitril/valsartan, a medicine used to treat a certain type of long-term (chronic) heart failure in adults, as this increases the risk of angioedema (rapid swelling of tissues under the skin, such as the throat).

If any of the above situations apply to the patient, they should not take Inhibace. In case of any doubts, before taking Inhibace, the patient should consult a doctor or pharmacist.

Warnings and precautions

Before taking Inhibace, the patient should consult a doctor or pharmacist if:

• the patient has heart disease. Inhibace should not be taken by patients with certain heart diseases;
• the patient has had a stroke or cerebral blood flow disorders in the past;
• the patient is taking any of the following medicines for high blood pressure:
• an angiotensin II receptor antagonist (also known as sartans - e.g., valsartan, telmisartan, irbesartan), especially if the patient has kidney problems related to diabetes;
• aliskiren; The doctor may monitor kidney function, blood pressure, and electrolyte levels (e.g., potassium) in the blood at regular intervals. See also the information under the heading "When not to take Inhibace";
• the patient is taking immunosuppressive medicines;
• the patient has severe liver disease or jaundice;
• the patient has kidney disease or renal blood flow disorders, known as renal artery stenosis;
• the patient is undergoing dialysis;
• the patient has recently experienced vomiting or diarrhea;
• the patient is on a low-sodium diet;
• the patient is scheduled for desensitization to bee or wasp venom;
• the patient is scheduled for surgery (including dental surgery). Some anesthetics may lower blood pressure, causing it to become too low;
• the patient has fluid in the abdominal cavity (ascites);
• the patient has diabetes or is taking anti-diabetic medicines;
• the patient has collagen vascular disease;
• the patient is undergoing low-density lipoprotein (LDL) apheresis using dextran sulfate.

If the patient is taking any of the following medicines, the risk of angioedema may increase:

• racecadotril, a medicine used to treat diarrhea;
• medicines used to prevent transplant rejection and to treat cancer (e.g., temsirolimus, sirolimus, everolimus);
• vildagliptin, a medicine used to treat diabetes.

If any of the above situations apply to the patient or in case of any doubts before taking Inhibace, the patient should consult a doctor or pharmacist.
The patient should inform their doctor if they suspect (or plan) pregnancy. It is not recommended to take Inhibace in early pregnancy and it should not be taken after the third month of pregnancy, as it may seriously harm the baby (see "Pregnancy" and "Breast-feeding").

Children and adolescents

Inhibace is not recommended for use in children.

Inhibace and other medicines

The patient should tell their doctor or pharmacist about all medicines they have taken recently. This includes medicines obtained without a prescription and herbal medicines. This is because Inhibace may affect the action of other medicines. Some medicines may also affect the action of Inhibace.
The doctor may need to change the dose and/or take other precautions: If the patient is taking an angiotensin II receptor antagonist (ARB) or aliskiren (see also the information in the sections "When not to take Inhibace" and "Warnings and precautions").
In particular, the patient should inform their doctor or pharmacist if they are currently taking, have recently taken, or might take any of the following medicines:

• diuretics - see the section "High blood pressure (hypertension)" in section 3 "How to take Inhibace";
• any medicines used to treat high blood pressure;
• non-steroidal anti-inflammatory drugs (NSAIDs). These include acetylsalicylic acid, indomethacin, and ibuprofen;
• insulin or other anti-diabetic medicines;
• lithium (used to treat depression);
• corticosteroids (such as hydrocortisone, prednisolone, and dexamethasone) or other immunosuppressive medicines;
• potassium supplements (including salt substitutes), potassium-sparing diuretics, and other medicines that increase potassium levels in the blood (e.g., trimethoprim and co-trimoxazole, used to treat bacterial infections; cyclosporine, an immunosuppressive medicine used to prevent transplant rejection, and heparin, a medicine used to thin the blood to prevent blood clots);
• aldosterone antagonists;
• sympathomimetics;
• anesthetics, narcotic analgesics;
• tricyclic antidepressants, antipsychotic medicines;
• gold compounds (used to treat rheumatoid arthritis).

Inhibace with food and drink

The patient should inform their doctor or pharmacist if they are taking dietary supplements containing potassium.

Pregnancy

Before taking Inhibace, the patient should consult their doctor if they suspect they are pregnant or plan to become pregnant. The patient should inform their doctor if they suspect (or plan) pregnancy.
The doctor will usually advise stopping Inhibace before planned pregnancy or as soon as pregnancy is confirmed and recommend taking a different medicine instead of Inhibace. It is not recommended to take Inhibace in early pregnancy and it should not be taken after the third month of pregnancy, as it may seriously harm the baby.

Breast-feeding

Before taking Inhibace, the patient should consult their doctor if they are breast-feeding or plan to breast-feed. The patient should inform their doctor if they are breast-feeding or plan to breast-feed. It is not recommended to take Inhibace during breast-feeding, especially when breast-feeding a newborn or premature baby. The doctor may recommend a different medicine.

Driving and using machines

While taking Inhibace, dizziness may occur. This is more likely at the start of treatment. If the patient experiences dizziness, they should not drive, use tools, or operate machinery.

Inhibace contains lactose monohydrate

Inhibace contains lactose monohydrate, a type of sugar. If the doctor has told the patient that they have an intolerance to some sugars, they should consult their doctor before taking Inhibace.

Inhibace contains sodium

This medicine contains less than 1 mmol of sodium (23 mg) per tablet, which is essentially "sodium-free".

3. How to take Inhibace

Inhibace should always be taken as directed by the doctor. In case of doubts, the patient should consult their doctor or pharmacist again.
Inhibace is available in the following strengths: 1 mg, 2.5 mg, 5 mg.

High blood pressure (hypertension)

• The usual initial dose in adults is 1 mg per day.
• The doctor will increase the dose until blood pressure is normalized - the usual maintenance dose is between 2.5 mg and 5 mg per day.
• The doctor may recommend a lower dose for patients with kidney problems or in elderly patients.
• If the patient is taking diuretics, the doctor may recommend stopping them about 3 days before starting Inhibace. The usual initial dose of Inhibace is then 0.5 mg per day. The doctor will then increase the dose until blood pressure is normalized.

Chronic heart failure

• The usual initial dose is 0.5 mg per day.
• The doctor will then increase the dose - the usual maintenance dose is between 1 mg and 2.5 mg per day.
• The doctor may recommend a lower dose for patients with kidney problems or in elderly patients.
• For patients with liver cirrhosis without ascites, the doctor will not recommend a dose higher than 0.5 mg per day and will closely monitor blood pressure.

Taking the medicine

• The tablet should be swallowed with water.
• The time of taking the tablet does not matter. However, the patient should take the tablet at the same time every day.
• Inhibace can be taken before or after a meal.
• The tablet can be divided into equal doses.

Taking a higher dose of Inhibace than recommended

In case of taking a higher dose of Inhibace than recommended or taking the medicine by another person, the patient should contact their doctor or go to the nearest hospital as soon as possible. They should take the packaging of the medicine with them. The following symptoms may occur: dizziness or a feeling of "emptiness" in the head, shallow breathing, cold and moist skin, inability to move or speak, and slow heart rate.

Missing a dose of Inhibace

• In case of missing a dose, the patient should skip the missed dose. Then, they should take the next dose at the usual time.
• The patient should not take a double dose (two doses at once) to make up for the missed dose.

In case of doubts about taking the medicine, the patient should consult their doctor or pharmacist.

4. Possible side effects

Like all medicines, Inhibace can cause side effects, although not everybody gets them.

Some side effects may be serious and may require immediate medical attention:

In case of a severe reaction called angioedema or an allergic reaction, the patient should stop taking Inhibace and go to their doctor as soon as possible. Symptoms include:

• sudden swelling of the face, throat, lips, or mouth. This swelling may cause difficulty breathing or swallowing.

In case of the following blood disorders, the patient should contact their doctor immediately:

• low red blood cell count (anemia). Symptoms include feeling tired, pale skin, fast or irregular heartbeat (palpitations), and shortness of breath.
• low white blood cell count (neutropenia, agranulocytosis). Symptoms include increased number of infections, such as mouth, gum, throat, and lung infections.
• low platelet count (thrombocytopenia). Symptoms include easy bruising and bleeding from the nose.

Other possible side effects:

Common(occurring in less than 1 in 10 people)

• dizziness
• cough
• nausea
• fatigue
• headache

Uncommon(occurring in less than 1 in 100 people)

• low blood pressure. This may cause weakness, dizziness, blurred vision, and fainting. Excessive lowering of blood pressure in some patients may increase the risk of heart attack or stroke
• fast heart rate
• weakness
• chest pain
• breathing difficulties, including shortness of breath and chest tightness
• runny or blocked nose and sneezing (rhinitis)
• dryness or swelling of the mouth
• loss of appetite
• change in taste
• diarrhea and vomiting
• rash (which may be severe)
• muscle cramps or muscle pain, or joint pain
• impotence
• increased sweating
• sudden flushing (especially of the face)
• sleep disturbances

Rare(occurring in less than 1 in 1000 people)

• decreased red and white blood cell or platelet count, found in blood tests (anemia, neutropenia, agranulocytosis, and thrombocytopenia)
• severe allergic reaction (anaphylactic reaction)
• brain hypoperfusion, transient ischemic attack, ischemic stroke (may occur if blood pressure is too low)
• myocardial infarction (may occur if blood pressure is too low)
• heart rhythm disorders
• interstitial lung disease
• systemic lupus erythematosus-like disorders
• tingling or numbness of hands or feet
• wheezing
• feeling of pressure or pulsating pain behind the nose, cheeks, and eyes (sinusitis)
• tongue pain
• pancreatitis. Symptoms include severe abdominal pain radiating to the back
• changes in kidney or liver function (shown in blood and urine tests)
• liver disorders, such as hepatitis or liver damage
• severe skin reactions, including blisters or skin peeling
• increased sensitivity to light
• hair loss (which may be temporary)
• loosening or separation of the nail from the nail bed
• breast enlargement in men

Reporting side effects

If side effects occur, including those not listed in the leaflet, the patient should tell their doctor or pharmacist. Side effects can be reported directly to the Department of Drug Safety Monitoring of Medicinal Products, Medical Devices, and Biocidal Products, Al. Jerozolimskie 181C, 02-222 Warsaw, tel.: +48 22 49 21 301, fax: +48 22 49 21 309, website: https://smz.ezdrowie.gov.pl.
Reporting side effects will help to gather more information on the safety of the medicine.

5. How to store Inhibace

Keep out of sight and reach of children.
There are no special storage instructions.
Do not take Inhibace after the expiry date stated on the packaging.
The expiry date refers to the last day of the month.
Medicines should not be disposed of via wastewater or household waste. The patient should ask their pharmacist how to dispose of medicines they no longer use. This will help protect the environment.

6. Contents of the packaging and other information

What Inhibace contains

• The active substance of Inhibace is cylazapril.
• Each coated tablet contains 5 mg of cylazapril in the form of cylazapril monohydrate (5.22 mg).
• Other ingredients of the medicine are: lactose monohydrate, corn starch, hypromellose 2910/3, talc, sodium stearylfumarate, Coating:hypromellose 2910/6, talc, titanium dioxide (E 171), iron oxide red (E 172). (See section 2: Inhibace contains lactose monohydrate)

What Inhibace looks like and contents of the packaging

Red-brown, oval, biconvex coated tablets with a dividing line on one side and the inscription "CIL 5" on the other side.
The packaging contains 28 coated tablets.
Al/Al blisters in a cardboard box.
For more detailed information, the patient should contact the marketing authorization holder or the parallel importer.

Marketing authorization holder in the Czech Republic, the country of export:

CHEPLAPHARM Arzneimittel GmbH
Ziegelhof 24
17489 Greifswald
Germany

Manufacturer:

CHEPLAPHARM Arzneimittel GmbH
Ziegelhof 23-24
17489 Greifswald
Germany

Parallel importer:

InPharm Sp. z o.o.
ul. Strumykowa 28/11
03-138 Warsaw

Repackaged by:

InPharm Sp. z o.o. Services sp. k.
ul. Chełmżyńska 249
04-458 Warsaw
Marketing authorization number in the Czech Republic, the country of export:58/080/03-C
Parallel import authorization number:268/09

This medicinal product is authorized in the Member States of the European Economic Area under the following names:

Countries:

Austria, Belgium, Czech Republic, Hungary, Poland: Inhibace
Germany: Dynorm
Greece: Vascace
Italy: Inibace
Translation of the symbols of the days of the week on the packaging:
MON - PO - Monday,
TUE - ÚT - Tuesday,
WEN - ST - Wednesday,
THU - ČT - Thursday,
FRI - PÁ - Friday,
SAT - SO - Saturday,
SUN - NE - Sunday.

Date of leaflet approval: 03.12.2024

[Information about the trademark]